Archive for the ‘Phase III’ Category
Masitinib
Posted by kinasepro on April 3, 2009
Posted in PDGFR, Phase III, c-Kit, gleevec | 3 Comments »
Correction
Posted by kinasepro on July 18, 2007
Pfizer’s Jak3 inhibitor CP-690,550 was described earlier listed as Ph ii-iii. For some reason that was changed, and all of its furthest advanced trials are Phase 2.
Posted in JAK, Phase III | 1 Comment »
I don’t know’s on third
Posted by kinasepro on June 19, 2007
So TM asked for it, and while most of these are scatterred about the site… It’s not such a bad idea to have all the not-yet-approved kinase inhibitors currently active in US phase three clinical trials here in one place:
In a maybe-not-so-chronoligical order: Arxxant, Enzastaurin, Recentin, Zactima, Axitinib, Motesanib, CP-690,550, Pazopanib, and Tasigna.
Missing any?
Posted in Phase III | 7 Comments »
Tasigna
Posted by kinasepro on June 19, 2007
Posted in Novartis, Phase III, c-Kit, gleevec | Leave a Comment »
Pazopanib
Posted by kinasepro on June 19, 2007
aka GW-786034 is GSK’s ‘pan Vegfr’ inhibitor:

salt: hydrochloride
some chemistry here.
clinic: ph iii: RCC, WO/2002/05911
Posted in GSK, Phase III, VEGF | Leave a Comment »
Motesanib
Posted by kinasepro on June 19, 2007
Motesanib diphosphate, AMG-706 hits: Vegfr1,2,3, c-kit, Pdgfr-b, and Ret
![O=C(NC1=CC=C(C(C)(C)CN2)C2=C1)C3=CC=CN=C3N([H])CC4=CC=NC=C4](http://img230.imageshack.us/img230/6476/amgfw8.jpg)
Salt: bisphosphonate
Clinic Ph iii: NSCLC
Cancer Res.; WO/2002/066470
Posted in Amgen, PDGFR, Phase III, VEGF, c-Kit | Leave a Comment »
Axitinib
Posted by kinasepro on June 19, 2007
aka AG-013736 is a Pfizer Vegf / c-FMS compound via Agouron.

Salt: Tosylate?
Clinic Ph iii: Pancreatic Cancer
WO/2001/002369; process app; ‘06 Asco,
Posted in Pfizer, Phase III, VEGF, c-fms | Leave a Comment »


![O=C(/C=C/CN(C)C)NC3=CC2=C(N=CN=C2C=C3O[C@H]4COCC4)NC1=CC=C(C(Cl)=C1)F](http://img205.imageshack.us/img205/3294/bibwhy7.jpg)


